Perrigo Company (PRGO), Elan Corporation, plc (ADR) (ELN): Will This Be the Next Irish Biotech Acquisition?

Page 1 of 2

Perrigo Company (NYSE:PRGO)’s acquisition of Elan Corporation, plc (ADR) (NYSE:ELN) for $8.6 billion has been widely criticized by many as a way for Perrigo to avoid paying a high U.S. corporate tax rate. Analysts believe that Perrigo’s acquisition represents a shift where companies are seeking assets in low taxed countries to increase profitability. According to analysts, there were several companies that were bidding to acquire Elan, but with Elan acquired, which Irish company might be next?

Why is Ireland attractive?

Perrigo Company (NYSE:PRGO) is a $12 billion company that has increased 260% over the last five years. The company generated $3.4 billion in sales over the last 12 months and has an operating margin of 19.7%. The company is based in the U.S., therefore pays a 35% corporate tax rate. However, with the acquisition of Ireland’s Elan Corporation, plc (ADR) (NYSE:ELN), the company’s tax rate drops to 12.5%, and earnings could increase more than $700 million annually over a course of several years — due to the tax savings.

Perrigo Company (NASDAQ:PRGO)Not to mention, Perrigo Company (NYSE:PRGO) gains $2 billion in cash that was on Elan Corporation, plc (ADR) (NYSE:ELN)’s balance sheet, and a 50% market share of its multiple sclerosis drug Tysabri. Biogen Idec Inc. (NASDAQ:BIIB) markets Tysabri and pays a double-digit royalty on annual sales, which Perrigo will now receive. The drug has peak sales potential of $3 billion annually. Once the drug’s annual sales exceed $2.5 billion, Perrigo’s share will rise from 18% to 25%, which could equate to $750 million if peak sales are reached.

Looking at Perrigo Company (NYSE:PRGO) as a company, the benefit of tax savings plus the top line benefit from Tysabri makes the acquisition of Elan Corporation, plc (ADR) (NYSE:ELN) a wise long-term move. In fact, with other opportunities in Ireland, this one acquisition could lead to more just like it.

The best available target

In my opinion, while there are several acquisition opportunities based in Ireland, including Alkermes Plc (NASDAQ:ALKS), but I think that Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) is the most intriguing.

Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) is a company that should be on your radar as a potential takeover target. Unlike Elan Corporation, plc (ADR) (NYSE:ELN), Jazz markets its own drugs, including 10 total and a large pipeline. During Jazz’s last quarter, revenue grew 91.4% year-over-year as its narcolepsy drug Xyrem continues to grow: Xyrem accounted for 60% of the company’s $196 million in quarterly sales.

Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has annual sales of $680 million and trades with a market cap of $4.6 billion. To the naked eye, its 6.6 times sales valuation might appear pricey, but with an operating margin of 39.5%, Jazz trades at just 10 times next year’s earnings.

The reason that Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) produces such great profits is because it is based in Ireland. Therefore, Jazz enjoys the same 12.5% tax rate that made Elan Corporation, plc (ADR) (NYSE:ELN) so attractive, and also has explosive growth and a bright future with its pipeline.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click here to Read Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 74 percentage points in 2.5 years. Our beta is only 1.2 (download a FREE newsletter and see the details inside)

Lists

Best Selling Magazines in the World

Shortest People in History

The Most Celebrated Holidays in the World

Most Expensive Handbag Brands in the World

Top Selling Comic Book Issues of this Century

The Most Powerful Women in Politics

Best Paid DJs

Most Rebellious Female Artists

Best Paid TV Actresses of 2014

Best Paid Actors of 2014

Most Expensive Horses in the World

Tallest People Ever

Most Encouraging Feminist Celebrities

Best Paid Supermodels of 2014

Top 10 Suburbs for Retirement in 2015

10 Wealthiest Cities in America

Top 10 TED Talks for Entrepreneurs

Best TED Talks on Education

25 Most Dangerous Places to Live in America

Top 10 Ski Resorts in the United States – 2014 List

Top 10 Most Remote Places in the World

Most Visited Museums in the United States

Wealthiest Photographers in the World

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!